Full-Time

Director – Pharmacovigilance Scientist

Cullinan Oncology

Cullinan Oncology

51-200 employees

Develops diversified oncology assets via portfolio

Compensation Overview

$210k - $270k/yr

+ Bonus + Equity Grants + 401(k) Match + Stock Options + ESPP

Cambridge, MA, USA

Hybrid

Category
Biology & Biotech (2)
,
Requirements
  • MS, PhD, or PharmD
  • Previous experience as PV/drug safety or clinical research safety (preferably in early clinical development) typically with 8-10 years of experience
  • Ability to utilize safety system database (Argus) for purposes of medical case review and simple queries
  • Knowledge of current and emerging regulatory requirements and expectations including ICH guidelines, EMA GVP Modules, FDA IND and NDA reporting requirements, CIOMS
  • Have led the authoring/preparation of aggregate safety reports (DSURs) for products to meet regulatory requirements
  • Effective written and oral communication skills
  • Demonstrated presentation and collaboration skills
Responsibilities
  • Provide complete Cullinan product life-cycle support for assigned product(s) and participate in clinical study team meetings as appropriate for assigned products
  • Represent PV for assigned compounds as a PV lead in cross-functional teams, including Cullinan Safety Management Team (SMT), Safety Review committee (SRC) and other teams with members external to Cullinan.
  • Perform ongoing quality review of ICSR representing company review in accordance with study Safety Management Plans, Safety exchange agreements, and SOPs.
  • Perform signal detection activities for assigned products in line with approved safety surveillance plan
  • Perform signal evaluation for any identified signals and author the safety evaluation report
  • Ensure timely, quality reports/safety analyses related to core deliverables with oversight as appropriate
  • Analyze the safety data, prepare and deliver presentations at SMT meetings
  • Responsible for authoring, preparation and review of safety documents including DSUR, response to health authority or other stakeholder safety queries etc.
  • Collaborate with clinical/Medical team to foster communication of potential safety concerns
  • Alert the Head of PV and Medical Safety Physicians to potential safety issues recognized through single case medical review or aggregated data sets
  • Participate and collaborate with the Clinical/Medical team in other risk management/mitigation activities in the clinical studies as appropriate for assigned compounds
  • Responsible for authoring the RSI section of the IB with an ability to provide expectedness of events for regulatory reporting purposes
  • Responsible for authoring the safety section in collaboration with team members on regulatory responses, IBs, review Informed Consent Forms (ICFs), CRFs, and providing the necessary quality control for safety assessment
  • Participate and collaborate with Clinical/Medical function in the development of protocols, and ensure safety oversight in cooperation/leadership of the clinical trial medical team
  • Ensure timely, quality reports/safety analyses related to core deliverables with oversight as appropriate
  • Serve as a Pharmacovigilance resource to the cross-functional teams
  • Collaborate with clinical/Medical team to foster communication of the potential safety concerns
  • Able to work with and collaborate with Pharmacovigilance Operations (PVO) to manage PV related activities by CRO
  • Participate and collaborate with PVO for SAE reconciliation activities between the clinical and safety databases in accordance with SOPs
  • Participating in and collaborating with PVO in the process improvement initiatives e.g. the development and maintenance of relevant SOPs, WIs and supporting documents
  • Review and provide input and support with other departments (e.g., clinical/medical, clinical operations, medical information, regulatory affairs, and data management) groups on PV-related topics for study protocols, statistical analysis plans, and other clinical-related documents
Desired Qualifications
  • Experience primarily in immunology and oncology therapeutic areas and any relevant experience or understanding of CART-cell therapy or T Cell engagers would be preferred
  • Passion, dedication, and a can-do attitude to the career of PVS, able to multi-task

Cullinan Oncology develops cancer treatments by managing a diverse set of oncology assets using a portfolio approach. The company advances therapies from preclinical stages to Phase 2 clinical trials, either on its own or through partnerships, and generates revenue from development and eventual commercialization. Its product(s) work by progressing promising compounds through clinical trials to show safety and efficacy across different cancer types, with a focus on mechanisms of action that broaden potential benefits. Cullinan differentiates itself with a modern portfolio theory-inspired asset mix, aiming to balance risk and return across many indications while maintaining a lean structure with almost no fixed costs for capital efficiency. The goal is to bring transformative cancer therapies to patients and improve the standard of care, pursuing both internal development and strategic partnerships to maximize value.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • $280M oversubscribed placement extends cash runway into 2029.
  • Zipalertinib advances in Phase 3 for $6B EGFR-NSCLC market.
  • CLN-978 Phase 1 recruits for rheumatoid arthritis and Sjögren’s.

What critics are saying

  • Taiho terminates zipalertinib co-development, halts Phase 3 funding.
  • CLN-049 Phase 1 fails versus Syndax revumenib in AML.
  • Cash burn exhausts runway by mid-2028, forces dilutive financing.

What makes Cullinan Oncology unique

  • Portfolio model diversifies oncology assets across indications and mechanisms.
  • Lean infrastructure ensures nearly zero fixed costs for capital efficiency.
  • T cell engagers expertise expands from oncology to autoimmune diseases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cullinan Oncology who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

4%
PR Newswire
Feb 11th, 2026
EGFR-NSCLC market to reach $6B with 9.6% CAGR as ADCs and TKIs reshape treatment landscape

DelveInsight forecasts the EGFR-NSCLC market will grow at a 9.6% CAGR from 2025 to 2034, reaching $6 billion across seven major markets in 2024. The United States accounts for the largest market share. Growth drivers include approval of new therapies such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), and Sacituzumab Tirumotecan (Merck/Kelun-Biotech) in frontline and combination settings, rising therapy costs, and increasing testing rates enabling identification of more EGFR-positive patients. The emerging pipeline includes TKIs, antibody-drug conjugates, bispecifics, and gene therapies from companies including ArriVent BioPharma, Bristol-Myers Squibb, and AbbVie. Adenocarcinoma represents the highest number of histology-specific cases. Recent clinical trials show promising results, with some candidates demonstrating over 80% objective response rates in treatment-naïve patients.

GlobeNewswire
Apr 16th, 2024
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to...

Defense World
Mar 10th, 2024
Federated Hermes Inc. Acquires New Holdings in Cullinan Oncology, Inc. (NASDAQ:CGEM)

Federated Hermes Inc. acquires new Holdings in Cullinan Oncology, Inc. (NASDAQ:CGEM).

Defense World
Mar 4th, 2024
Algert Global LLC Invests $150,000 in Cullinan Oncology, Inc. (NASDAQ:CGEM)

Algert Global LLC invests $150,000 in Cullinan Oncology, Inc. (NASDAQ:CGEM).

BioSpace
Nov 20th, 2023
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Under Mr. Hughes's leadership, Cullinan raised over $400 million in capital through its initial public offering and advanced several assets into the clinic.